Table 2.
Univariate and multivariate analyses of overall survival
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P‐value | HR | 95% CI | P‐value | |
| Treatment | ||||||
| Observation | 1.00 | .0285a | 1.00 | .0283a | ||
| R‐maintenance | 0.43 | (0.20, 0.91) | 0.42 | (0.19, 0.91) | ||
| Gender | ||||||
| Female | 1.00 | .3759 | 1.00 | .5422 | ||
| Male | 0.71 | (0.33, 1.52) | 0.78 | (0.35, 1.73) | ||
| Age (years) | ||||||
| 20‐59 | 1.00 | .0064a | 1.00 | .0252a | ||
| More than 60 | 2.97 | (1.36, 6.48) | 2.58 | (1.13, 5.91) | ||
| Charlson comorbidity index | ||||||
| 0 | 1.00 | .1944 | 1.00 | .4384 | ||
| 1 | 2.01 | (0.84, 4.79) | 1.65 | (0.68, 4.01) | ||
| 2+ | 2.02 | (0.72, 5.61) | 1.70 | (0.59, 4.88) | ||
| Ann Arbor stage | ||||||
| II‐III | 1.00 | .0375a | 1.00 | .0258a | ||
| IV | 2.29 | (1.05, 5.01) | 2.47 | (1.12, 5.47) | ||
| Practice setting | ||||||
| Medical center | 1.00 | .1620 | 1.00 | .0643 | ||
| Others | 1.75 | (0.80, 3.82) | 2.21 | (0.95, 5.12) | ||
| Induction treatment | ||||||
| R‐CHOP | 1.00 | .9926 | 1.00 | .3941 | ||
| R‐others | 1.00 | (0.47, 2.17) | 0.70 | (0.31, 1.59) | ||
| Rituximab cycles in induction treatment | ||||||
| 4‐6 cycles | 1.00 | .9857 | 1.00 | .6301 | ||
| 7‐8 cycles | 1.01 | (0.45, 2.24) | 0.82 | (0.36, 1.86) | ||
R‐maintenance, rituximab maintenance.
a
P‐value is <.05.